Relative Intelligence · Biotechnology

How Regeneron Pharmaceuticals (REGN) compares with the whole market and its popular alternatives
Built by QuantCommons' quantitative engine, this page is about relative opportunity, not data on REGN alone. It places REGN (Regeneron Pharmaceuticals, Inc.) against 20+ popular alternatives, its neighboring categories and the entire market of over 10,000 U.S.-listed stocks and ETFs, and surfaces what has done better on consistent outperformance, return for the risk taken, behavior in real market crashes and diversification. The result is a clearer view of where REGN stands in the market, and of the alternatives worth a closer look.
Period covered: REGN's full trading record, from April 1991 through September 2026. All returns include reinvested dividends. Data as of October 20, 2026.
Data as of October 20, 2026. Full tables and charts read best on a larger screen.
On this page12 sections
Key findings
- Right nowThe slide is REGN's own: it is 32.2% below its high, against 1.3% for the S&P 500. On the flip side, REGN has run far ahead of the market, rising 20.3% over the past 3 months against 3.9% for the S&P 500 and 3.2% for the Nasdaq 100. At a glance ↓
- Stock or market?REGN's 20.3% gain over the past 3 months far outran its industry: the biotechnology ETF XBI (State Street SPDR S&P Biotech ETF) rose 1.5%. The S&P 500 rose 3.9%. Its biotechnology peers did not move as one over the past 3 months: HALO (Halozyme Therapeutics) rose 61.3%, while ARGX (argenx) rose 2.8%.
- Past 1 to 3 yearsOver the past year, REGN rose 40.7% against 15.8% for the S&P 500 and 17.9% for the Nasdaq 100. Even so, REGN led its biotechnology peers in 2023, then fell behind AMGN (Amgen) and BIIB (Biogen) in 2025. By year ↓
- Long termREGN turned $10,000 into $22,000 over the past decade, against $42,100 in the S&P 500. Growth of $10,000 ↓
- In a crashAcross seven sell-offs, REGN has typically fallen 1.3 times as far as the S&P 500. Crash tests ↓
- DiversificationREGN is a real diversifier: a correlation of 0.08 with the S&P 500 over 5 years and 0.07 with the total US market, less closely than 96% of stocks worth at least $300 million. On the flip side, over 10 years, REGN's beta versus the S&P 500 was 0.19: 55% of the S&P 500's gains in rising months and 66% of its losses in falling ones. Market capture ↓
- Better options
- Nearby categories and themes
- MRK (Merck & Co., Inc., pharmaceuticals) and TAK (Takeda Pharmaceutical, pharmaceuticals) earned more than REGN with less volatility over the past 5 years. MRK returned 16.3% a year at 24.8% volatility, against 7.7% a year at 31.1%.
- Whole market
- 688 of the 3,633 stocks and funds worth at least $500 million earned more than REGN with less volatility over the past 5 years, among them AAPL (Apple), MSFT (Microsoft) and VTI (Vanguard Morningstar Total Stock Market ETF).
How much would $10,000 in REGN have grown?
This chart tracks a hypothetical $10,000 investment in REGN over the past 29 years, with dividends reinvested, alongside the same amount in the S&P 500, investments that ended ahead of REGN over the same span and REGN's popular alternatives, among those that traded for the entire period. A second view covers the past 5 years, the period the better options further down the page are judged on. It shows not only where each investment ended up but also how smooth or uneven the path was.
- $10,000 invested in REGN at the end of September 1997 would have grown to $683,800 by September 2026, more than the $132,907 it would have become in SPY, an S&P 500 fund.
- Five of the eight other investments on the chart ended ahead of REGN, and AAPL finished highest, at $20,534,853.
Choose a period
From the end of September 1997 to the end of September 2026. The scale is logarithmic, so equal steps up the chart are equal percentage gains. Hover over a fund in the key to pick out its line. 62 of the 1,042 stocks and funds worth at least $500 million that traded the whole period ended ahead of REGN; the chart shows 5, closest alternatives first. The other 3 lines are popular alternatives, shown for context.
- AAPL$21M+205,249% total · +30.1% a year
- GILD$2M+15,614% total · +19.1% a year
- TJX$958,745+9,487% total · +17.0% a year
- DHR$777,394+7,674% total · +16.2% a year
- COST$727,732+7,177% total · +15.9% a year
- REGN$683,800+6,738% total · +15.7% a year
- AMGN$526,909+5,169% total · +14.6% a year
- LLY$396,376+3,864% total · +13.5% a year
- TMO$235,386+2,254% total · +11.5% a year
- SPY (S&P 500)$132,907+1,229% total · +9.3% a year
From the end of September 2021 to the end of September 2026. Hover over a fund in the key to pick out its line. 2,014 of the 3,628 stocks and funds worth at least $500 million that traded the whole period ended ahead of REGN; the chart shows 5, closest alternatives first. The other 3 lines are popular alternatives, shown for context.
- LLY$52,411+424% total · +39.3% a year
- VRTX$28,822+188% total · +23.6% a year
- EXEL$27,629+176% total · +22.5% a year
- HALO$27,138+171% total · +22.1% a year
- GILD$25,496+155% total · +20.6% a year
- AMGN$23,160+132% total · +18.3% a year
- PCVX$22,428+124% total · +17.5% a year
- SPY (S&P 500)$19,000+90.0% total · +13.7% a year
- REGN$12,649+26.5% total · +4.8% a year
- TMO$11,986+19.9% total · +3.7% a year
REGN at a glance
This section summarizes the key facts about the stock, its returns over periods from one to ten years and the risk it has carried, with dividends reinvested throughout. These figures serve as the baseline for every comparison that follows.
- REGN is still 32.2% below its all-time high.
- REGN's deepest decline since it began trading in 1991 was 91.8%, from February 2000 to April 2005. It took about six years from the low to climb back to its old high.
- Over 29 full calendar years, REGN's best was 2012, when it returned 209%, and its worst was 1997, when it lost 46.9%. It lost money in ten of those years.
The company
- Market value
- $83B
- Industry
- Biotechnology
- Price history from
- April 1991
Returns
- Past 1 year
- +40.7%total return
- Past 3 years
- +0.8%+0.3% a year
- Past 5 years
- +44.9%+7.7% a year
- Past 10 years
- +120%+8.2% a year
- Best calendar year
- +209%2012
- Worst calendar year
- −46.9%1997
- Losing years
- 10 of 29full calendar years
Risk
- Volatility
- 31.1%typical yearly swing, 5 years
- Sharpe ratio
- 0.40return per unit of risk, 5 years
- Worst decline ever
- −91.8%Feb 2000 to Apr 2005
- From its all-time high
- −32.2%below the peak
REGN against the whole market
Where REGN ranks among every stock and fund, and what across the market has done better.
How does REGN rank among all stocks?
This section ranks REGN on return, volatility, risk-adjusted return and worst decline against every stock worth at least $300 million with enough history. Where the comparisons with its popular alternatives show how REGN stacks up against its peers, these rankings show where it stands in the market as a whole.
- REGN's 3-year return ranks in the bottom 23% of the 3,017 stocks worth at least $300 million with 3 years of history.
- REGN's 1-year return ranks in the top 22% of the 3,287 stocks worth at least $300 million with 1 year of history.
Ranked against U.S.-listed stocks worth at least $300M that have enough history for each measure, so the count changes from row to row; smaller stocks are left out. Lower volatility and smaller declines rank higher.
| Measure | REGN | Rank | Standing |
|---|---|---|---|
| 1-year return | +40.7% | 718 of 3,287 | top 22% |
| 3-year return | +0.8% | 2,316 of 3,017 | bottom 24% |
| 5-year return | +44.9% | 1,149 of 2,893 | top 40% |
| 10-year return | +120% | 1,239 of 2,202 | bottom 45% |
| Volatility, 5 years | 31.1% | 837 of 2,893 | top 29% |
| Sharpe ratio, 5 years | 0.40 | 1,245 of 2,893 | top 43% |
| Worst decline, past 10 years | −59.7% | 866 of 2,187 | top 40% |
What has beaten REGN on both return and risk?
Each dot is an investment, placed by how much it earned a year over the past 5 years (higher is better) and how much its price swung, its volatility (further left is calmer). REGN sits where the dashed lines cross. Anything in the green box above and to the left earned more than REGN with smaller swings, a better trade-off over this period on both counts. Past results are no promise, but a name in the box is worth a closer look.
- 271 stocks and 417 ETFs worth at least $500 million sit in the green region: each earned more than REGN over the past 5 years with smaller price swings. That is 19% of the 3,633 screened.
- Among those with at least half REGN's swings, CAH has the best return for its risk: 42.1% a year at 24.7% volatility, 21% less than REGN's 31.1%, and a Sharpe ratio (return above cash per unit of volatility) of 1.55 against 0.40 for REGN.
- Among REGN's popular alternatives, GILD, VRTX and AMGN are in the region. GILD earned 22.8% a year against 7.7% a year for REGN, at 24.9% volatility, 20% less than REGN's 31.1%.
Annual return is the annualized total return with dividends reinvested, and volatility the annualized swing in daily prices, both over 5 years. Labeled dots are the strongest picks from the table below and the names called out above, colored by how close they sit to REGN; faint dots are 90 more of the 688 in the green region (the strongest, one per fund family). 3,633 stocks and funds worth at least $500 million were screened. Hover over a dot for its figures.
- Popular alternatives
- Same and neighboring categories, and shared themes
- The whole market
- Others in the green region
Is there a better investment than REGN?
Investments that beat REGN over the past 5 years on return, volatility, drawdowns, consistency, crash losses or fees, from its popular alternatives out to the whole market.
- Among REGN's popular alternatives, AMGN, GILD and VRTX earned more than REGN with less volatility over the past 5 years. AMGN returned 19.6% a year at 24.9% volatility, against 7.7% a year at 31.1%.
- Looking beyond its popular alternatives, MRK (pharmaceuticals) and TAK (pharmaceuticals) earned more than REGN with less volatility over the past 5 years. MRK returned 16.3% a year at 24.8% volatility, against 7.7% a year at 31.1%.
- Across the whole market, 688 of the 3,633 stocks and funds worth at least $500 million earned more than REGN with less volatility over the past 5 years, among them AAPL, MSFT and VTI.
How this works
The table below lists investments that beat REGN over the past 5 years on at least one of these measures: a higher annual return with lower volatility, a higher annual return at similar volatility, a similar return with lower volatility, a higher Sharpe ratio with a smaller worst decline, a higher total return in most periods from 3 months to 10 years, or smaller losses in recent market crashes. It checks REGN's popular alternatives first, then the rest of its own and neighboring categories, then every stock and fund worth at least $500 million, and shows the strongest few in each group. The full list of those with a higher return and lower volatility than REGN follows the table.
Annual return is the annualized total return with dividends reinvested. Annual return, volatility and the Sharpe ratio cover 5 years; the worst decline covers the past 10 years. Green marks a better figure than REGN's. "On the frontier" means no other option shown or tested earned more with less volatility. Funds that hold the same thing are shown once. Beyond the popular alternatives, nothing with more than 1.5× REGN's volatility counts as better.
These figures cover the past 5 years. Green marks a better figure than REGN's.
| Investment | Why it is better | Past 5 years | Downside | Long run | Fit | ||||
|---|---|---|---|---|---|---|---|---|---|
| Annual return?higher is better | Volatility?lower is calmer | Sharpe?return per unit of risk | Worst decline?past 10 years | 10Y returntotal | Corr. with REGN?lower diversifies more | Expenseper year | |||
| +7.7% | 31.1% | 0.40 | −59.7% | +120% | 1.00 | — | |||
| +12.7% | 17.1% | 0.79 | −33.7% | +321% | 0.08 | 0.09% | |||
| Popular alternativesbest 6 shownThe investments people most often weigh against REGN. 9 of 22 passed at least one test. | |||||||||
| Higher return, lower volatilityHigher Sharpe, smaller worst declineHigher return in most periods | +19.6% | 24.9% | 0.85 | −24.9% | +266% | 0.47 | — | ||
| Higher return, similar volatilityHigher Sharpe, smaller worst declineHigher return in most periods | +40.7% | 32.8% | 1.21 | −34.5% | +1,807% | 0.44 | — | ||
| Higher return, lower volatilityHigher Sharpe, smaller worst decline | +22.8% | 24.9% | 0.95 | −30.5% | +200% | 0.14 | — | ||
| Higher return, lower volatilityHigher Sharpe, smaller worst decline | +22.6% | 29.1% | 0.85 | −41.6% | +521% | 0.25 | — | ||
HALOHalozyme Therapeutics, Inc. · Biotechnology | Higher Sharpe, smaller worst declineHigher return in most periods | +26.6% | 40.4% | 0.79 | −49.1% | +1,196% | 0.25 | — | |
INCYIncyte Corporation · Biotechnology | Higher return, similar volatility | +12.2% | 30.1% | 0.53 | −66.5% | +31.8% | 0.29 | — | |
| Same and neighboring categories, and shared themesbest 6 shownEverything else in Biotechnology and the categories next to it (Pharmaceuticals, Life Sciences Tools, Contract Research), plus REGN's specific themes. 17 of 77 passed at least one test. | |||||||||
| Higher return, lower volatilityHigher Sharpe, smaller worst declineHigher return in most periods | +16.3% | 24.8% | 0.74 | −43.4% | +241% | 0.42 | — | ||
| Higher return, lower volatilityHigher Sharpe, smaller worst declineHigher return in most periods | +11.9% | 19.4% | 0.68 | −54.4% | +30.4% | 0.20 | — | ||
RPRXRoyalty Pharma plc · Pharmaceuticals | Higher return, lower volatilityHigher Sharpe, smaller worst declineHigher return in most periods | +13.3% | 23.8% | 0.65 | −49.7% | — | 0.16 | — | |
| Higher return, lower volatilityHigher Sharpe, smaller worst decline | +26.1% | 23.4% | 1.11 | −45.1% | +603% | 0.28 | — | ||
| Higher return, lower volatilityHigher Sharpe, smaller worst decline | +12.7% | 17.9% | 0.76 | −27.4% | +196% | 0.35 | — | ||
| Higher return, lower volatilityHigher Sharpe, smaller worst decline | +17.1% | 20.7% | 0.87 | −26.8% | +226% | 0.24 | — | ||
| The whole marketbest 8 shownEvery other stock and fund worth at least $500 million. 1,183 of 3,534 passed at least one test. | |||||||||
| On the frontierHigher return, lower volatilityHigher Sharpe, smaller worst declineHigher return in most periods | +42.1% | 24.7% | 1.55 | −46.1% | +349% | 0.11 | — | ||
| Higher return, lower volatilityHigher Sharpe, smaller worst declineHigher return in most periods | +12.5% | 28.2% | 0.56 | −37.1% | +946% | 0.08 | — | ||
| Higher return, lower volatilityHigher Sharpe, smaller worst declineHigher return in most periods | +16.8% | 26.1% | 0.73 | −42.0% | +374% | -0.08 | — | ||
| Higher return, lower volatilityHigher Sharpe, smaller worst declineHigher return in most periods | +38.7% | 25.0% | 1.44 | −38.1% | +586% | 0.17 | — | ||
| Higher return, lower volatilityHigher Sharpe, smaller worst declineHigher return in most periods | +15.8% | 20.0% | 0.84 | −42.0% | +310% | 0.01 | — | ||
SDCIUSCF SummerHaven Dynamic Commodity Strategy No K-1 Fund · Bonds | On the frontierHigher return, lower volatilityHigher Sharpe, smaller worst declineHigher return in most periods | +20.6% | 18.4% | 1.12 | −45.7% | — | 0.07 | 0.80% | |
| Higher return, similar volatilityHigher Sharpe, smaller worst declineHigher return in most periods | +33.6% | 30.6% | 1.10 | −45.7% | +345% | -0.12 | — | ||
| Similar return, lower volatilityHigher Sharpe, smaller worst decline | +8.2% | 16.4% | 0.57 | −36.0% | +140% | 0.05 | 0.05% | ||
What these numbers mean for REGN
- Annual return
- REGN returned 7.7% a year over the past 5 years with dividends reinvested, against 12.7% a year for the S&P 500. At that pace, $10,000 became about $14,500. Annual return is the steady yearly rate that would produce the same total result, so investments held over the same span compare fairly. Guide: What is performance and return? →
- Volatility
- REGN's volatility over the past 5 years was 31.1%, 1.8 times the S&P 500's 17.1%. Volatility measures how widely returns swing around their average: in roughly two years out of three, REGN's return lands within 31.1% of its average, either way. The higher it is, the rougher the ride and the harder it is to hold through a slump. Guide: Understanding and measuring risk (volatility) →
- Sharpe ratio
- REGN's Sharpe ratio over the past 5 years was 0.40, against 0.79 for the S&P 500, so REGN earned less for each unit of risk than an index fund did. The Sharpe ratio is the return earned above cash for each unit of volatility: two investments with the same return are not equal if one got there with far bigger swings. Guide: Balancing reward with risk (Sharpe ratio) →
- Worst decline
- REGN's worst fall from a peak to a low over the past 10 years was 59.7%, against 33.7% for the S&P 500. Losses and gains are not symmetric: climbing back from a 59.7% fall takes a 148% gain. Guide: Market crash risk and tail risk →
- Correlation
- Over the past 5 years, REGN's monthly returns had a correlation of 0.08 with the S&P 500. Correlation runs from 1 (moving in lockstep) through 0 (unrelated) to −1 (moving in opposite directions). They are close to unrelated, or move in opposite directions, so it can steady a stock portfolio. In the table, the correlation column measures each option against REGN instead: the lower it is, the more that option would diversify a REGN holding. Guide: Correlation and diversification →
Show all 688 stocks and funds worth at least $500 million that earned more than REGN with less volatility
Out of 3,633 tested over 5 years. The strongest 100 are listed, best first, with funds that hold the same thing listed once.
| # | Investment | Found in | Annual return | Volatility | Sharpe | Worst decline | 10Y return | Corr. with REGN | Expense |
|---|---|---|---|---|---|---|---|---|---|
| 1 | Whole market | +42.1% | 24.7% | 1.55 | −46.1% | +349% | 0.11 | — | |
| 2 | Whole market | +12.5% | 28.2% | 0.56 | −37.1% | +946% | 0.08 | — | |
| 3 | Whole market | +16.8% | 26.1% | 0.73 | −42.0% | +374% | -0.08 | — | |
| 4 | Whole market | +38.7% | 25.0% | 1.44 | −38.1% | +586% | 0.17 | — | |
| 5 | Whole market | +15.8% | 20.0% | 0.84 | −42.0% | +310% | 0.01 | — | |
| 6 | Whole market | +33.7% | 29.4% | 1.14 | −47.6% | +474% | -0.05 | — | |
| 7 | Whole market | +22.4% | 22.3% | 1.02 | −46.3% | +347% | 0.21 | — | |
| 8 | Whole market | +12.9% | 19.9% | 0.71 | −46.9% | +187% | 0.08 | — | |
| 9 | Whole market | +17.9% | 25.4% | 0.78 | −42.5% | +284% | 0.11 | — | |
| 10 | SDCIUSCF SummerHaven Dynamic Commodity Strategy No K-1 Fund · Bonds | Whole market | +20.6% | 18.4% | 1.12 | −45.7% | — | 0.07 | 0.80% |
| 11 | Whole market | +14.0% | 25.7% | 0.64 | −45.5% | +79.7% | 0.08 | — | |
| 12 | RSReliance Steel & Aluminum Co. · Metals & Mining | Whole market | +24.8% | 28.1% | 0.93 | −40.8% | +626% | 0.04 | — |
| 13 | EXPDExpeditors International of Washington, Inc. · Freight & Logistics | Whole market | +12.0% | 27.1% | 0.56 | −35.6% | +349% | 0.20 | — |
| 14 | Same or nearby category | +16.3% | 24.8% | 0.74 | −43.4% | +241% | 0.42 | — | |
| 15 | RNRRenaissanceRe Holdings Ltd. · Insurance | Whole market | +20.1% | 27.8% | 0.80 | −40.7% | +215% | 0.18 | — |
| 16 | EWTiShares MSCI Taiwan ETF · International Equity | Whole market | +20.4% | 24.2% | 0.89 | −38.9% | +468% | -0.16 | 0.59% |
| 17 | VLUEiShares MSCI USA Value Factor ETF · US Large-Cap Value | Whole market | +15.9% | 18.4% | 0.90 | −39.5% | +286% | -0.02 | 0.15% |
| 18 | MSGSMadison Square Garden Sports Corp. · Entertainment | Whole market | +18.4% | 25.6% | 0.79 | −41.6% | +432% | -0.05 | — |
| 19 | Popular alternative | +19.6% | 24.9% | 0.85 | −24.9% | +266% | 0.47 | — | |
| 20 | NHCNational HealthCare Corporation · Medical - Care Facilities | Whole market | +32.0% | 28.5% | 1.12 | −35.3% | +394% | 0.22 | — |
| 21 | Same or nearby category | +11.9% | 19.4% | 0.68 | −54.4% | +30.4% | 0.20 | — | |
| 22 | PDBCInvesco Optimum Yield Diversified Commodity Strategy No K-1 ETF · Broad Commodities | Whole market | +11.7% | 19.3% | 0.67 | −40.7% | +153% | 0.13 | 0.74% |
| 23 | FLTWFranklin FTSE Taiwan ETF · Technology | Whole market | +21.8% | 24.3% | 0.94 | −38.0% | — | -0.16 | 0.19% |
| 24 | RSPTInvesco S&P 500 Equal Weight Technology ETF · Technology Equity | Whole market | +16.9% | 25.1% | 0.75 | −33.7% | +572% | -0.05 | 0.40% |
| 25 | MSMMSC Industrial Direct Co., Inc. · Industrial Distribution | Whole market | +13.3% | 25.1% | 0.63 | −48.2% | +184% | 0.04 | — |
| 26 | PSMTPriceSmart, Inc. · Discount Retail | Whole market | +18.6% | 28.2% | 0.75 | −53.2% | +124% | 0.07 | — |
| 27 | RPRXRoyalty Pharma plc · Pharmaceuticals | Same or nearby category | +13.3% | 23.8% | 0.65 | −49.7% | — | 0.16 | — |
| 28 | Whole market | +17.3% | 18.2% | 0.97 | −40.0% | +352% | 0.12 | — | |
| 29 | FBTFirst Trust NYSE Arca Biotechnology Index Fund · Healthcare | Whole market | +10.8% | 22.2% | 0.58 | −33.3% | +203% | 0.25 | 0.55% |
| 30 | SRCE1st Source Corporation · Banks - Regional | Whole market | +15.1% | 27.0% | 0.66 | −51.7% | +210% | 0.13 | — |
| 31 | Whole market | +27.1% | 26.5% | 1.04 | −61.0% | +214% | 0.24 | — | |
| 32 | Whole market | +18.5% | 28.0% | 0.75 | −38.5% | +1,168% | 0.20 | — | |
| 33 | HBTHBT Financial, Inc. · Banks - Regional | Whole market | +18.9% | 28.7% | 0.75 | −54.0% | — | 0.12 | — |
| 34 | COMTiShares GSCI Commodity Dynamic Roll Strategy ETF · Commodities | Whole market | +13.1% | 21.1% | 0.69 | −39.2% | +160% | 0.07 | 0.49% |
| 35 | CTBICommunity Trust Bancorp, Inc. · Banks - Regional | Whole market | +16.0% | 26.0% | 0.70 | −43.0% | +192% | 0.01 | — |
| 36 | DJPiPath Bloomberg Commodity Index Total Return(SM) ETN · Commodities | Whole market | +11.2% | 18.9% | 0.66 | −38.4% | +120% | 0.10 | 0.70% |
| 37 | TRSTTrustCo Bank Corp NY · Banks - Regional | Whole market | +15.5% | 26.8% | 0.68 | −49.5% | +126% | 0.16 | — |
| 38 | THFFFirst Financial Corporation · Banks - Regional | Whole market | +15.9% | 26.2% | 0.69 | −42.8% | +161% | 0.03 | — |
| 39 | UVSPUnivest Financial Corporation · Banks - Regional | Whole market | +11.2% | 29.5% | 0.51 | −53.4% | +142% | 0.10 | — |
| 40 | FCBCFirst Community Bankshares, Inc. · Banks - Regional | Whole market | +14.0% | 28.7% | 0.60 | −49.5% | +217% | 0.05 | — |
| 41 | Whole market | +19.5% | 25.2% | 0.84 | −55.8% | +238% | 0.24 | — | |
| 42 | FBIZFirst Business Financial Services, Inc. · Banks - Regional | Whole market | +23.1% | 29.4% | 0.85 | −50.2% | +307% | 0.13 | — |
| 43 | RCBCRiver City Bank · Banks - Regional | Whole market | +14.6% | 27.2% | 0.64 | −45.5% | +345% | 0.05 | — |
| 44 | Whole market | +11.5% | 17.5% | 0.71 | −35.0% | +302% | 0.07 | 0.03% | |
| 45 | Whole market | +21.0% | 24.8% | 0.90 | −67.2% | +233% | 0.23 | — | |
| 46 | Whole market | +12.8% | 16.9% | 0.80 | −34.0% | +324% | 0.08 | 0.03% | |
| 47 | Whole market | +20.8% | 22.6% | 0.96 | −25.7% | +508% | 0.17 | — | |
| 48 | Whole market | +13.4% | 17.1% | 0.82 | −29.6% | +274% | 0.34 | — | |
| 49 | Whole market | +17.3% | 24.3% | 0.78 | −43.6% | +537% | 0.12 | — | |
| 50 | Whole market | +12.8% | 22.9% | 0.64 | −36.4% | +429% | 0.04 | — | |
| 51 | Whole market | +23.0% | 25.6% | 0.94 | −61.4% | +278% | 0.26 | — | |
| 52 | Whole market | +16.0% | 28.7% | 0.66 | −63.9% | +141% | 0.26 | — | |
| 53 | DXJWisdomTree Japan Hedged Equity Fund · International Equity | Whole market | +26.6% | 19.1% | 1.34 | −39.1% | +428% | 0.05 | 0.48% |
| 54 | Whole market | +22.6% | 24.0% | 0.97 | −57.5% | +373% | 0.15 | — | |
| 55 | LVHIFranklin International Low Volatility High Dividend Index ETF · International Equity | Whole market | +17.0% | 11.1% | 1.48 | −32.4% | +194% | 0.24 | 0.40% |
| 56 | Whole market | +14.7% | 16.8% | 0.91 | −37.0% | +204% | 0.28 | — | |
| 57 | Whole market | +17.4% | 22.9% | 0.82 | −31.4% | +685% | 0.16 | — | |
| 58 | Whole market | +14.5% | 23.0% | 0.71 | −35.1% | +553% | -0.04 | 0.18% | |
| 59 | Whole market | +12.4% | 23.8% | 0.61 | −41.0% | +541% | 0.11 | — | |
| 60 | Whole market | +21.0% | 23.4% | 0.94 | −42.9% | +242% | -0.10 | — | |
| 61 | Whole market | +12.1% | 13.7% | 0.90 | −36.8% | +235% | 0.17 | 0.03% | |
| 62 | Whole market | +22.6% | 25.5% | 0.93 | −66.8% | +189% | 0.24 | 0.08% | |
| 63 | Whole market | +18.6% | 24.3% | 0.83 | −52.0% | +317% | 0.10 | — | |
| 64 | Whole market | +19.6% | 28.6% | 0.77 | −48.8% | +521% | -0.01 | — | |
| 65 | Whole market | +9.3% | 16.9% | 0.61 | −35.8% | +153% | 0.10 | 0.03% | |
| 66 | Whole market | +16.0% | 28.8% | 0.66 | −51.3% | +627% | -0.06 | — | |
| 67 | Whole market | +13.3% | 28.0% | 0.59 | −80.2% | +233% | 0.17 | — | |
| 68 | Whole market | +19.9% | 22.3% | 0.93 | −42.5% | +361% | 0.24 | — | |
| 69 | Whole market | +17.7% | 18.9% | 0.96 | −26.4% | +213% | 0.02 | 0.40% | |
| 70 | Whole market | +11.5% | 20.9% | 0.63 | −32.6% | +394% | 0.07 | — | |
| 71 | Whole market | +18.4% | 26.0% | 0.78 | −35.1% | +779% | -0.06 | 0.09% | |
| 72 | KOFCoca-Cola FEMSA, S.A.B. de C.V. · Food & Beverages | Whole market | +22.3% | 24.7% | 0.94 | −55.1% | +119% | 0.09 | — |
| 73 | Whole market | +27.4% | 28.8% | 0.99 | −54.7% | +789% | 0.12 | — | |
| 74 | Whole market | +13.5% | 29.3% | 0.58 | −49.6% | +446% | 0.04 | — | |
| 75 | Whole market | +21.3% | 25.6% | 0.89 | −30.3% | +816% | 0.12 | — | |
| 76 | IHGInterContinental Hotels Group PLC · Hotels & Resorts | Whole market | +21.4% | 26.6% | 0.86 | −59.3% | +383% | 0.04 | — |
| 77 | PAAPlains All American Pipeline, L.P. · Oil & Gas Midstream | Whole market | +27.0% | 25.6% | 1.06 | −87.9% | +64.0% | 0.17 | — |
| 78 | Whole market | +15.7% | 20.4% | 0.82 | −42.6% | +248% | 0.25 | — | |
| 79 | Whole market | +17.8% | 21.4% | 0.88 | −53.7% | +140% | -0.04 | — | |
| 80 | Whole market | +22.7% | 24.4% | 0.97 | −50.5% | +341% | 0.06 | — | |
| 81 | Whole market | +19.2% | 21.6% | 0.93 | −47.3% | +395% | 0.09 | — | |
| 82 | Whole market | +10.4% | 14.1% | 0.78 | −31.7% | +258% | 0.17 | 0.04% | |
| 83 | Whole market | +22.7% | 27.7% | 0.88 | −40.5% | +955% | -0.01 | — | |
| 84 | Whole market | +24.2% | 22.8% | 1.07 | −32.4% | +406% | 0.22 | — | |
| 85 | Whole market | +9.7% | 14.3% | 0.72 | −33.4% | +252% | 0.24 | 0.06% | |
| 86 | Whole market | +13.6% | 21.4% | 0.71 | −51.0% | +295% | -0.03 | — | |
| 87 | Whole market | +9.8% | 25.2% | 0.50 | −39.4% | +60.7% | 0.15 | — | |
| 88 | Whole market | +26.3% | 24.9% | 1.07 | −41.6% | +654% | -0.03 | — | |
| 89 | Whole market | +12.2% | 29.0% | 0.54 | −37.5% | +464% | 0.12 | — | |
| 90 | RGAReinsurance Group of America, Incorporated · Insurance | Whole market | +19.7% | 27.3% | 0.80 | −65.8% | +199% | 0.16 | — |
| 91 | Whole market | +21.0% | 26.8% | 0.85 | −50.8% | +694% | 0.16 | — | |
| 92 | Whole market | +17.2% | 24.9% | 0.77 | −30.4% | +285% | -0.11 | — | |
| 93 | Whole market | +11.1% | 24.2% | 0.56 | −36.7% | +204% | 0.08 | — | |
| 94 | Whole market | +10.3% | 16.2% | 0.69 | −34.2% | +223% | 0.07 | 0.06% | |
| 95 | Whole market | +11.3% | 18.8% | 0.67 | −38.4% | +170% | 0.02 | — | |
| 96 | Whole market | +16.5% | 23.1% | 0.78 | −48.4% | +808% | 0.19 | — | |
| 97 | Whole market | +11.2% | 20.8% | 0.62 | −37.4% | +319% | 0.15 | — | |
| 98 | Whole market | +12.9% | 20.8% | 0.69 | −51.6% | +184% | 0.17 | — | |
| 99 | Whole market | +17.4% | 29.1% | 0.70 | −46.4% | +426% | 0.00 | — | |
| 100 | Whole market | +9.1% | 18.9% | 0.56 | −44.1% | +103% | 0.10 | — |
REGN against its popular alternatives
The investments people most often weigh against REGN, compared period by period and year by year.
How do REGN's risk and return compare with its alternatives?
This map plots each investment's annual return over the past 5 years against its volatility, the size of its typical price swings. Investments toward the upper left earned more for a smoother ride, and those toward the lower right earned less for a rougher one. The dashed lines cross at REGN, which divides the map into what did better or worse on each measure.
- Four of the 22 popular alternatives, led by GILD, VRTX and AMGN, were both more rewarding and calmer than REGN over the past 5 years, earning a higher annual return with lower volatility.
- Over the past 5 years, REGN returned 7.7% a year, less than the S&P 500's 12.7%, with higher volatility (31.1% against 17.1%).
Green points earned more than REGN with less volatility; red points earned less with more. Hover over a point for its figures. Total returns with dividends reinvested, annualized.
All figures
| Investment | Annual return | Volatility |
|---|---|---|
| LLY Eli Lilly and Company | +40.7% | 32.8% |
| HALO Halozyme Therapeutics, Inc. | +26.7% | 40.4% |
| EXEL Exelixis, Inc. | +24.4% | 35.8% |
| PCVX Vaxcyte, Inc. | +24.3% | 64.1% |
| ARGX argenx SE | +24.1% | 39.9% |
| UTHR United Therapeutics Corporation | +23.6% | 35.1% |
| GILD Gilead Sciences, Inc. | +22.8% | 24.9% |
| VRTX Vertex Pharmaceuticals Incorporated | +22.6% | 29.1% |
| AMGN Amgen Inc. | +19.6% | 24.9% |
| SPY S&P 500State Street SPDR S&P 500 ETF | +12.7% | 17.1% |
| INCY Incyte Corporation | +12.2% | 30.1% |
| PTCT PTC Therapeutics, Inc. | +11.9% | 55.0% |
| IONS Ionis Pharmaceuticals, Inc. | +8.3% | 43.9% |
| REGN This pageRegeneron Pharmaceuticals, Inc. | +7.7% | 31.1% |
| NBIX Neurocrine Biosciences, Inc. | +6.6% | 33.2% |
| TMO Thermo Fisher Scientific Inc. | +2.9% | 27.8% |
| ALNY Alnylam Pharmaceuticals, Inc. | +2.5% | 50.9% |
| SNY Sanofi | +0.6% | 25.3% |
| BIIB Biogen Inc. | −1.8% | 34.7% |
| DHR Danaher Corporation | −3.8% | 29.1% |
| BMRN BioMarin Pharmaceutical Inc. | −5.6% | 33.0% |
| BNTX BioNTech SE | −19.3% | 52.6% |
| SRPT Sarepta Therapeutics, Inc. | −24.8% | 70.3% |
| RARE Ultragenyx Pharmaceutical Inc. | −26.9% | 58.4% |
Has REGN consistently beaten its popular alternatives?
This section compares REGN with the investments people most often weigh against it, checking each one over eight periods from one month to ten years. Counting how often an alternative earned more than REGN helps separate lasting outperformance from a single strong stretch.
- Seven of the 22 popular alternatives, led by HALO, AMGN and LLY, outperformed REGN in at least 3 of 5 short-term and 2 of 3 long-term timeframes.
- HALO, AMGN and LLY outperformed REGN in every long-term period and in all but one short-term period, the most consistent record in the group.
- LLY, GILD and VRTX earned more for the risk they took than REGN (a higher Sharpe ratio) and fell less in their worst decline of the past 10 years.
A green cell means the alternative earned more than REGN over that period. "Qualified" marks those that did so in at least 3 of 5 short-term periods and 2 of 3 long-term periods.
| Investment | Periods outperformed | Short term | Long term | Risk · 5 years | Fund | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Volatilitylower is calmer | Sharpehigher is better | Worst declinepast 10 years | Expense | Assets | Overlapsame sectors | ||
| REGN Regeneron Pharmaceuticals, Inc. (this page) | — | +1.2% | +20.3% | +8.0% | +4.4% | +40.7% | +0.8% | +44.9% | +120% | 31.1% | 0.40 | −59.7% | — | $83B | — |
| HALO QualifiedHalozyme Therapeutics, Inc. | 5/5 short3/3 longAll-weather | +11.6% | +61.3% | +78.8% | +76.9% | +87.1% | +254% | +226% | +1,196% | 40.4% | 0.79 | −49.1% | — | $14B | — |
| AMGN QualifiedAmgen Inc. | 5/5 short3/3 longAll-weather | +11.6% | +21.2% | +27.0% | +36.7% | +48.7% | +72.2% | +145% | +266% | 24.9% | 0.85 | −24.9% | — | $237B | — |
| LLY QualifiedEli Lilly and Company | 4/5 short3/3 longAll-weather | +10.2% | +12.1% | +40.0% | +19.4% | +59.7% | +124% | +451% | +1,807% | 32.8% | 1.21 | −34.5% | — | $1.2T | — |
| EXEL QualifiedExelixis, Inc. | 4/5 short3/3 longAll-weather | +12.5% | +16.0% | +47.6% | +47.8% | +86.4% | +205% | +198% | +448% | 35.8% | 0.79 | −57.2% | — | $16B | — |
| GILD QualifiedGilead Sciences, Inc. | 3/5 short3/3 long | +4.0% | +18.2% | +16.6% | +31.0% | +30.3% | +121% | +180% | +200% | 24.9% | 0.95 | −30.5% | — | $194B | — |
| TMO QualifiedThermo Fisher Scientific Inc. | 4/5 short2/3 long | +4.3% | +30.7% | +30.9% | +16.3% | +26.8% | +49.5% | +15.1% | +366% | 27.8% | 0.24 | −40.9% | — | $254B | — |
| PCVX QualifiedVaxcyte, Inc. | 3/5 short2/3 long | +12.4% | +19.3% | +6.8% | +42.6% | +54.4% | +41.5% | +197% | — | 64.1% | 0.65 | −76.2% | — | $10B | — |
| VRTX BiotechnologyVertex Pharmaceuticals Incorporated | 2/5 short3/3 long | +0.8% | +7.1% | +17.2% | +13.8% | +22.8% | +42.2% | +177% | +521% | 29.1% | 0.85 | −41.6% | — | $130B | — |
| UTHR BiotechnologyUnited Therapeutics Corporation | 2/5 short3/3 long | +12.3% | +4.6% | −3.4% | +11.5% | +28.0% | +146% | +188% | +390% | 35.1% | 0.78 | −55.6% | — | $24B | — |
| PTCT BiotechnologyPTC Therapeutics, Inc. | 0/5 short3/3 long | −3.6% | −19.3% | −13.0% | −18.0% | −8.0% | +171% | +75.4% | +796% | 55.0% | 0.48 | −73.8% | — | $5.3B | — |
| DHR Medical - Diagnostics & ResearchDanaher Corporation | 2/5 short2/3 long | +4.0% | +11.6% | +15.0% | −2.2% | +8.3% | +10.8% | −17.6% | +232% | 29.1% | 0.01 | −43.8% | — | $157B | — |
| INCY BiotechnologyIncyte Corporation | 2/5 short2/3 long | −6.4% | +0.8% | +20.3% | +15.0% | +35.3% | +112% | +77.6% | +31.8% | 30.1% | 0.53 | −66.5% | — | $24B | — |
| ALNY BiotechnologyAlnylam Pharmaceuticals, Inc. | 0/5 short2/3 long | −5.6% | −15.4% | −25.8% | −42.3% | −53.0% | +42.6% | +13.2% | +514% | 50.9% | 0.29 | −58.2% | — | $31B | — |
| NBIX BiotechnologyNeurocrine Biosciences, Inc. | 0/5 short2/3 long | −1.4% | −17.9% | +7.9% | +1.0% | +0.5% | +28.6% | +37.4% | +211% | 33.2% | 0.36 | −46.4% | — | $14B | — |
| ARGX Biotechnologyargenx SE | 0/5 short2/3 long | −12.0% | +2.8% | +4.2% | +3.5% | +2.4% | +83.1% | +194% | — | 39.9% | 0.74 | −38.2% | — | $54B | — |
| IONS BiotechnologyIonis Pharmaceuticals, Inc. | 0/5 short1/3 long | +1.1% | −14.3% | −39.4% | −43.0% | −38.3% | −1.6% | +48.8% | +58.8% | 43.9% | 0.40 | −70.4% | — | $7.5B | — |
| BIIB Drug Manufacturers - GeneralBiogen Inc. | 5/5 short0/3 long | +11.0% | +21.6% | +32.6% | +36.7% | +65.8% | −5.6% | −8.8% | −18.9% | 34.7% | 0.11 | −72.7% | — | $36B | — |
| RARE BiotechnologyUltragenyx Pharmaceutical Inc. | 1/5 short0/3 long | +9.4% | −43.8% | −36.1% | −32.1% | −53.4% | −51.6% | −79.2% | −75.9% | 58.4% | -0.22 | −92.7% | — | $1.6B | — |
| SNY Drug Manufacturers - GeneralSanofi | 0/5 short0/3 long | −2.6% | −5.9% | −10.3% | −10.7% | −13.4% | −10.0% | +3.0% | +61.5% | 25.3% | 0.15 | −33.5% | — | $99B | — |
| BMRN BiotechnologyBioMarin Pharmaceutical Inc. | 0/5 short0/3 long | −11.9% | −4.5% | +2.8% | −5.1% | +6.3% | −31.3% | −24.9% | −33.0% | 33.0% | -0.01 | −62.1% | — | $11B | — |
| SRPT BiotechnologySarepta Therapeutics, Inc. | 0/5 short0/3 long | −4.8% | +13.9% | −10.5% | −10.0% | −16.8% | −82.8% | −76.0% | −60.9% | 70.3% | -0.03 | −93.3% | — | $2.0B | — |
| BNTX BiotechnologyBioNTech SE | 0/5 short0/3 long | −7.0% | −1.1% | −13.3% | −5.7% | −15.5% | +0.3% | −65.7% | — | 52.6% | -0.15 | −82.3% | — | $23B | — |
How did REGN do year by year?
This table shows each investment's total return in every full calendar year since 1997, along with where REGN ranked among its popular alternatives each year. Annual results reveal how consistently each one kept pace with REGN and how far its good and bad years diverged, detail that multiyear averages tend to smooth over.
- REGN finished ahead of the S&P 500 in 17 of its 29 full calendar years, and behind it in each of the last three.
- Among its popular alternatives, ARGX came out ahead of REGN most often, in five of the eight years both traded.
- Ranked against its popular alternatives each year, REGN finished in the top quarter in seven of 29 years and in the bottom quarter in five. In 2025, it ranked 15 of 23.
Newest year first. Green marks a year in which the fund came out ahead of REGN; gray means the two finished within a fraction of a point. The rank row places REGN among the alternatives that traded the full year; dark green is the top quarter and red the bottom quarter.
| Investment | Years ahead of REGN | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 | 1998 | 1997 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| REGN This pageRegeneron Pharmaceuticals, Inc. | — | +9.0% | −18.9% | +21.7% | +14.2% | +30.7% | +28.7% | +0.5% | −0.7% | +2.4% | −32.4% | +32.3% | +49.0% | +60.9% | +209% | +68.8% | +35.8% | +31.7% | −24.0% | +20.3% | +26.2% | +72.7% | −37.4% | −20.6% | −34.3% | −20.2% | +177% | +72.8% | −13.8% | −46.9% |
| Rank among alternatives | Top quarter in 7 of 29 | 15 of 23 | 20 of 23 | 6 of 23 | 14 of 23 | 6 of 23 | 10 of 22 | 16 of 21 | 11 of 21 | 18 of 20 | 15 of 20 | 7 of 20 | 6 of 19 | 10 of 18 | 2 of 18 | 1 of 18 | 5 of 18 | 8 of 18 | 9 of 18 | 9 of 18 | 8 of 18 | 3 of 18 | 15 of 16 | 15 of 16 | 8 of 15 | 12 of 15 | 2 of 14 | 4 of 12 | 9 of 12 | 11 of 11 |
| SPY S&P 500State Street SPDR S&P 500 ETF | 12 of 29 | +17.7% | +24.9% | +26.2% | −18.2% | +28.7% | +18.3% | +31.2% | −4.6% | +21.7% | +12.0% | +1.2% | +13.5% | +32.3% | +16.0% | +1.9% | +15.1% | +26.4% | −36.8% | +5.1% | +15.9% | +4.8% | +10.7% | +28.2% | −21.6% | −11.7% | −9.8% | +20.4% | +28.7% | +33.5% |
| HALO Halozyme Therapeutics, Inc. | 10 of 21 | +40.8% | +29.4% | −35.0% | +41.5% | −5.9% | +141% | +21.2% | −27.8% | +105% | −43.0% | +79.6% | −35.6% | +123% | −29.4% | +20.1% | +34.9% | +4.8% | −21.2% | −11.7% | +342% | −17.3% | — | — | — | — | — | — | — | — |
| AMGN Amgen Inc. | 15 of 29 | +29.7% | −6.8% | +13.5% | +20.4% | +0.9% | −2.0% | +27.6% | +15.2% | +22.3% | −7.6% | +4.0% | +42.3% | +34.8% | +36.8% | +18.2% | −3.0% | −2.0% | +24.3% | −32.0% | −13.4% | +22.9% | +3.8% | +27.8% | −14.4% | −11.7% | +6.5% | +130% | +93.3% | −0.4% |
| LLY Eli Lilly and Company | 17 of 29 | +40.3% | +33.3% | +60.9% | +34.3% | +66.1% | +31.0% | +16.2% | +40.5% | +17.8% | −10.4% | +25.4% | +39.8% | +7.3% | +24.2% | +25.2% | +3.6% | −6.2% | −21.3% | +5.7% | −5.2% | +2.6% | −17.6% | +13.1% | −17.6% | −14.4% | +41.9% | −24.3% | +29.1% | +93.6% |
| EXEL Exelixis, Inc. | 10 of 25 | +31.6% | +38.8% | +49.6% | −12.3% | −8.9% | +13.9% | −10.4% | −35.3% | +104% | +164% | +292% | −76.5% | +34.1% | −3.6% | −42.3% | +11.4% | +46.8% | −41.8% | −4.1% | −4.5% | −0.8% | +34.8% | −11.9% | −51.9% | +13.6% | — | — | — | — |
| GILD Gilead Sciences, Inc. | 15 of 29 | +36.6% | +18.7% | −2.0% | +23.6% | +29.9% | −6.7% | +7.9% | −9.9% | +3.0% | −27.6% | +8.6% | +25.5% | +105% | +79.5% | +12.9% | −16.3% | −15.4% | +11.2% | +41.7% | +23.4% | +50.2% | +20.1% | +71.4% | +3.6% | +58.2% | +53.9% | +31.7% | +6.7% | +53.6% |
| TMO Thermo Fisher Scientific Inc. | 17 of 29 | +11.8% | −1.7% | −3.4% | −17.3% | +43.5% | +43.7% | +45.6% | +18.2% | +35.0% | −0.1% | +13.8% | +13.1% | +75.8% | +43.2% | −18.8% | +16.1% | +40.0% | −40.9% | +27.4% | +50.3% | −0.2% | +19.8% | +25.3% | −15.7% | +5.6% | +98.2% | −11.4% | −61.5% | +6.7% |
| PCVX Vaxcyte, Inc. | 3 of 5 | −43.6% | +30.3% | +31.0% | +102% | −10.5% | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| VRTX Vertex Pharmaceuticals Incorporated | 17 of 29 | +12.6% | −1.0% | +40.9% | +31.5% | −7.1% | +7.9% | +32.1% | +10.6% | +103% | −41.4% | +5.9% | +59.9% | +77.3% | +26.2% | −5.2% | −18.3% | +41.0% | +30.8% | −37.9% | +35.2% | +162% | +2.1% | −34.7% | −35.5% | −65.6% | +309% | +17.6% | −9.8% | −18.0% |
| UTHR United Therapeutics Corporation | 13 of 26 | +38.1% | +60.5% | −20.9% | +28.7% | +42.4% | +72.3% | −19.1% | −26.4% | +3.1% | −8.4% | +20.9% | +14.5% | +112% | +13.1% | −25.3% | +20.1% | +68.3% | −35.9% | +79.7% | −21.3% | +53.1% | +96.7% | +37.5% | +60.3% | −29.4% | −67.9% | — | — | — |
| PTCT PTC Therapeutics, Inc. | 6 of 12 | +68.3% | +63.8% | −27.8% | −4.2% | −34.7% | +27.1% | +40.0% | +106% | +52.9% | −66.3% | −37.4% | +205% | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| DHR Danaher Corporation | 16 of 29 | +0.4% | −0.4% | −1.2% | −19.0% | +48.6% | +45.4% | +49.5% | +11.8% | +20.0% | +73.2% | +9.3% | +11.6% | +38.3% | +19.1% | −0.1% | +25.7% | +33.0% | −35.4% | +21.3% | +30.1% | −2.7% | +25.3% | +39.7% | +9.1% | −11.7% | +41.5% | −11.0% | +72.4% | +35.2% |
| INCY Incyte Corporation | 12 of 29 | +43.0% | +10.0% | −21.8% | +9.4% | −15.6% | −0.4% | +37.3% | −32.9% | −5.5% | −7.5% | +48.3% | +44.4% | +205% | +10.7% | −9.4% | +81.8% | +140% | −62.3% | +72.1% | +9.4% | −46.6% | +46.1% | +50.0% | −76.5% | −21.9% | −17.1% | +60.5% | −16.9% | +74.7% |
| ALNY Alnylam Pharmaceuticals, Inc. | 11 of 21 | +69.0% | +22.9% | −19.5% | +40.1% | +30.5% | +12.8% | +58.0% | −42.6% | +239% | −60.2% | −2.9% | +50.8% | +252% | +124% | −17.3% | −44.0% | −28.7% | −15.0% | +35.9% | +60.2% | +78.8% | — | — | — | — | — | — | — | — |
| NBIX Neurocrine Biosciences, Inc. | 14 of 29 | +3.9% | +3.6% | +10.3% | +40.2% | −11.1% | −10.8% | +50.5% | −8.0% | +100% | −31.6% | +153% | +139% | +24.9% | −12.0% | +11.3% | +181% | −15.0% | −29.5% | −56.4% | −83.4% | +27.2% | −9.6% | +19.4% | −11.0% | +54.9% | +33.9% | +260% | −12.7% | −21.2% |
| ARGX argenx SE | 5 of 8 | +36.7% | +61.7% | +0.4% | +8.2% | +19.1% | +83.2% | +67.1% | +52.1% | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| IONS Ionis Pharmaceuticals, Inc. | 17 of 29 | +126% | −30.9% | +33.9% | +24.1% | −46.2% | −6.4% | +11.8% | +7.5% | +5.2% | −22.8% | +0.3% | +55.0% | +282% | +44.8% | −28.7% | −8.9% | −21.6% | −10.0% | +41.6% | +112% | −11.2% | −9.2% | −1.4% | −70.3% | +109% | +70.1% | −51.7% | +5.1% | −31.6% |
| BIIB Biogen Inc. | 12 of 29 | +15.1% | −40.9% | −6.6% | +15.4% | −2.0% | −17.5% | −1.4% | −5.5% | +12.3% | −7.4% | −9.8% | +21.4% | +91.0% | +33.0% | +64.1% | +25.3% | +12.3% | −16.3% | +15.7% | +8.6% | −32.0% | +81.5% | +10.6% | −51.9% | +9.1% | +93.0% | +318% | +36.6% | +44.7% |
| RARE Ultragenyx Pharmaceutical Inc. | 3 of 11 | −45.3% | −12.0% | +3.2% | −44.9% | −39.3% | +224% | −1.8% | −6.3% | −34.0% | −37.3% | +156% | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| SNY Sanofi | 7 of 23 | +4.9% | +1.1% | +6.5% | +0.5% | +7.0% | +0.4% | +20.5% | +6.0% | +9.9% | −1.2% | −3.4% | −11.9% | +17.1% | +36.0% | +18.8% | −13.4% | +28.7% | −26.5% | +1.0% | +7.2% | +11.6% | +8.2% | +26.2% | — | — | — | — | — | — |
| BMRN BioMarin Pharmaceutical Inc. | 9 of 26 | −9.6% | −31.8% | −6.8% | +17.1% | +0.8% | +3.7% | −0.7% | −4.5% | +7.6% | −20.9% | +15.9% | +28.5% | +43.0% | +43.1% | +27.7% | +43.2% | +5.7% | −49.7% | +116% | +52.0% | +68.7% | −17.6% | +10.1% | −47.5% | +38.7% | −17.5% | — | — | — |
| SRPT Sarepta Therapeutics, Inc. | 13 of 28 | −82.3% | +26.1% | −25.6% | +43.9% | −47.2% | +32.1% | +18.2% | +96.1% | +103% | −28.9% | +167% | −29.0% | −21.1% | +473% | −64.6% | +45.2% | +121% | −53.2% | −55.7% | −7.8% | +46.8% | −42.3% | −18.6% | −54.2% | +130% | −12.7% | +36.0% | −41.3% | — |
| BNTX BioNTech SE | 3 of 6 | −16.4% | +8.0% | −29.7% | −41.0% | +216% | +141% | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Risk and diversification
How REGN has fallen, how it held up in crashes beside the S&P 500 and its popular alternatives, and what moves independently of it.
What were REGN's worst declines?
A drawdown is the decline from a peak to the lowest point before a new high. This section presents REGN's five deepest drawdowns since it began trading in 1991, alongside the S&P 500's return over the same dates, and how long each took to recover. Together, these figures show how much an investor could have lost and how long it took to get back to even.
- In all four of REGN's worst declines, the S&P 500 held up better over the same dates.
- Not every decline was the market's doing: REGN fell 77.4% from October 1996 to April 1999, while the S&P 500 rose 96.7%.
- The slowest recovery came after REGN fell 91.8% from February 2000 to April 2005; it did not regain that peak until April 2011, six years later.
Green means REGN fell less than the S&P 500 over the same dates. Based on daily closing prices with dividends reinvested.
| During | REGN fell | S&P 500, same dates | Peak | Low | Time to the low | Back at the peak | Time to recover |
|---|---|---|---|---|---|---|---|
| Dot-com bust | −91.8% | −8.9% | Feb 2000 | Apr 2005 | 5.2 years | Apr 2011 | 6 years |
| No named crash | −86.7% | — | Feb 1992 | Dec 1994 | 2.8 years | Oct 1996 | 22 months |
| No named crash | −77.4% | +96.7% | Oct 1996 | Apr 1999 | 2.5 years | Feb 2000 | 10 months |
| No named crash | −59.7% | +6.6% | Aug 2024 | Jun 2025 | 10 months | Not yet | — |
| 2015 China and oil sell-off | −53.8% | +53.0% | Aug 2015 | Sep 2019 | 4.1 years | May 2020 | 8 months |
How did REGN do in stock market crashes?
This section measures how far REGN, the S&P 500 and each alternative fell from peak to trough during every major market crash since 2000. A smaller decline means an investment held up better, and comparing results across crashes shows whether that resilience was consistent or a one-off.
- Among its popular alternatives, AMGN held up best, falling less than REGN in seven of the ten crashes they both traded through.
- REGN fell further than the S&P 500 in six of the ten crashes it has traded through. The clearest case was the 2015 China and oil sell-off, when REGN fell 37.7% and the S&P 500 fell 12.8%.
Newest crash first. Each figure is the fund's deepest fall within the crash window; green means a smaller fall than REGN.
| Investment | Held up better | 2023 regional bank crisisMar 2023 | 2022 bear marketJan 2022 | Covid crashFeb 2020 | Late-2018 sell-offSep 2018 | February 2018 volatility shockFeb 2018 | 2015 China and oil sell-offAug 2015 | 2011 euro debt crisisJul 2011 | 2010 flash crashMay 2010 | 2008 financial crisisOct 2007 | Dot-com bustMar 2000 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| REGN This pageRegeneron Pharmaceuticals, Inc. | — | −0.2% | −25.8% | −12.7% | −17.3% | −7.3% | −37.7% | −23.2% | −7.2% | −49.9% | −71.6% |
| SPY S&P 500State Street SPDR S&P 500 ETF | 6 of 10 | −3.4% | −24.5% | −33.7% | −19.3% | −6.5% | −12.8% | −17.9% | −1.5% | −55.2% | −47.5% |
| HALO Halozyme Therapeutics, Inc. | 1 of 9 | −2.6% | −25.6% | −36.3% | −28.6% | −7.1% | −66.0% | −21.1% | −7.6% | −70.6% | — |
| AMGN Amgen Inc. | 7 of 10 | −1.2% | −11.9% | −18.3% | −14.3% | −7.4% | −22.1% | −12.6% | −0.5% | −31.3% | −60.2% |
| LLY Eli Lilly and Company | 6 of 10 | −0.6% | −11.7% | −16.9% | −10.2% | −8.6% | −19.6% | −10.9% | 0.0% | −50.0% | −54.3% |
| EXEL Exelixis, Inc. | 2 of 9 | 0.0% | −35.4% | −33.7% | −24.9% | −8.7% | −36.4% | −43.7% | −5.4% | −80.0% | — |
| GILD Gilead Sciences, Inc. | 7 of 10 | −1.6% | −20.0% | −13.7% | −22.7% | −5.5% | −28.7% | −18.2% | −2.1% | −34.3% | −53.6% |
| TMO Thermo Fisher Scientific Inc. | 4 of 10 | −2.4% | −19.8% | −24.8% | −17.2% | −8.7% | −14.7% | −24.4% | −3.6% | −53.9% | −41.8% |
| PCVX Vaxcyte, Inc. | 0 of 2 | −8.2% | −33.5% | — | — | — | — | — | — | — | — |
| VRTX Vertex Pharmaceuticals Incorporated | 2 of 10 | 0.0% | −19.2% | −19.4% | −21.2% | −8.8% | −43.7% | −23.9% | −2.7% | −59.9% | −86.7% |
| UTHR United Therapeutics Corporation | 4 of 10 | −1.8% | −22.3% | −31.2% | −21.2% | −5.3% | −31.3% | −35.1% | −3.5% | −57.8% | −93.2% |
| PTCT PTC Therapeutics, Inc. | 0 of 6 | −8.2% | −43.4% | −45.5% | −36.8% | −7.4% | −47.7% | — | — | — | — |
| DHR Danaher Corporation | 7 of 10 | −3.2% | −22.8% | −25.9% | −13.4% | −9.8% | −14.0% | −21.8% | −0.6% | −45.7% | −33.7% |
| INCY Incyte Corporation | 4 of 10 | −2.4% | −20.4% | −23.7% | −16.4% | −4.8% | −50.2% | −32.9% | −4.5% | −83.5% | −97.1% |
| ALNY Alnylam Pharmaceuticals, Inc. | 1 of 9 | −4.1% | −28.9% | −30.0% | −33.7% | −6.9% | −48.9% | −39.3% | −1.5% | −58.6% | — |
| NBIX Neurocrine Biosciences, Inc. | 3 of 10 | −3.5% | −24.3% | −27.9% | −45.1% | −5.7% | −44.1% | −32.8% | −7.1% | −83.0% | −65.8% |
| ARGX argenx SE | 1 of 5 | 0.0% | −26.0% | −32.8% | −19.8% | −1.2% | — | — | — | — | — |
| IONS Ionis Pharmaceuticals, Inc. | 2 of 10 | −5.8% | −26.3% | −32.6% | −18.1% | −8.5% | −48.8% | −25.7% | −2.1% | −45.6% | −74.6% |
| BIIB Biogen Inc. | 5 of 10 | −2.5% | −22.4% | −21.2% | −21.7% | −9.3% | −24.6% | −19.4% | −0.6% | −52.7% | −59.8% |
| RARE Ultragenyx Pharmaceutical Inc. | 0 of 6 | −8.8% | −56.5% | −45.1% | −56.9% | −9.6% | −61.4% | — | — | — | — |
| SNY Sanofi | 5 of 9 | −0.5% | −33.5% | −25.2% | −9.0% | −9.8% | −30.2% | −20.7% | −2.8% | −46.6% | — |
| BMRN BioMarin Pharmaceutical Inc. | 2 of 10 | −4.5% | −22.9% | −26.3% | −24.4% | −11.6% | −53.6% | −23.1% | −4.1% | −74.9% | −89.7% |
| SRPT Sarepta Therapeutics, Inc. | 1 of 10 | −6.7% | −29.7% | −33.6% | −39.7% | −12.6% | −74.3% | −39.5% | −5.0% | −84.4% | −87.3% |
| BNTX BioNTech SE | 0 of 3 | −1.2% | −45.7% | −49.5% | — | — | — | — | — | — | — |
How closely does REGN move with the S&P 500?
Upside capture measures how much of the S&P 500's gains an investment kept in the months the market rose, and downside capture how much of its losses it took in the months the market fell. An investment that captures more of the gains than the losses has compounded ahead of the market over time. This section compares REGN with its popular alternatives on both measures, and on beta (how strongly each has moved with the market), over the past 10 years.
- Over the past 10 years, REGN captured 55% of the S&P 500's gains in rising months and 66% of its losses in falling months, with a beta of 0.19. Its share of the market's losses was larger than its share of the gains.
- 12 of the 19 popular alternatives had a higher capture ratio (upside capture divided by downside capture) than REGN's 0.84, led by LLY, VRTX and EXEL.
- LLY took just 6% of the S&P 500's losses, against 66% for REGN, while still keeping 101% of its gains.
Monthly total returns over the past 10 years, measured against SPY. 100% capture or a beta of 1.00 means moving in line with the S&P 500. Green marks a better figure than REGN's: more upside, less downside or a higher capture ratio. Sorted by capture ratio.
| Investment | Upside capture | Downside capture | Capture ratio | Beta |
|---|---|---|---|---|
| REGN This pageRegeneron Pharmaceuticals, Inc. | 55% | 66% | 0.84 | 0.19 |
| LLY Eli Lilly and Company | 101% | 6% | 15.73 | 0.37 |
| VRTX Vertex Pharmaceuticals Incorporated | 87% | 50% | 1.75 | 0.46 |
| EXEL Exelixis, Inc. | 74% | 43% | 1.72 | 0.73 |
| UTHR United Therapeutics Corporation | 75% | 45% | 1.66 | 0.52 |
| GILD Gilead Sciences, Inc. | 52% | 36% | 1.44 | 0.35 |
| HALO Halozyme Therapeutics, Inc. | 129% | 102% | 1.27 | 1.15 |
| AMGN Amgen Inc. | 74% | 64% | 1.16 | 0.54 |
| NBIX Neurocrine Biosciences, Inc. | 69% | 66% | 1.04 | 0.56 |
| DHR Danaher Corporation | 84% | 84% | 1.01 | 0.75 |
| TMO Thermo Fisher Scientific Inc. | 104% | 104% | 1.00 | 0.81 |
| ALNY Alnylam Pharmaceuticals, Inc. | 92% | 93% | 0.99 | 0.73 |
| PTCT PTC Therapeutics, Inc. | 112% | 115% | 0.97 | 0.85 |
| SNY Sanofi | 53% | 74% | 0.72 | 0.46 |
| INCY Incyte Corporation | 52% | 87% | 0.60 | 0.77 |
| IONS Ionis Pharmaceuticals, Inc. | 71% | 125% | 0.56 | 0.74 |
| BIIB Biogen Inc. | 35% | 91% | 0.38 | 0.28 |
| SRPT Sarepta Therapeutics, Inc. | 71% | 217% | 0.33 | 0.89 |
| BMRN BioMarin Pharmaceutical Inc. | 20% | 70% | 0.29 | 0.38 |
| RARE Ultragenyx Pharmaceutical Inc. | 19% | 142% | 0.13 | 1.07 |
What diversifies REGN?
Correlation measures how closely two investments move together, on a scale from 1 (in lockstep) through 0 (unrelated) to -1 (in opposite directions). This section lists large ETFs and stocks whose returns have had a low correlation with REGN's. Because such investments tend not to fall at the same time, pairing REGN with them can reduce a portfolio's overall swings.
- Moving a fifth of the money in REGN into SPMO would have cut the portfolio's volatility by 20% over the past 5 years and raised its annual return (+4.8% for REGN alone, +9.1% for the mix).
- Among large ETFs, LVHI, DXJ and EMLP have moved largely independently of REGN over the past 5 years, with correlations of 0.24 or lower, and each still earned a positive 5-year return.
- FIX made money in six of the ten calendar years in which REGN lost money.
Only ETFs with at least $1.0B in assets and stocks worth at least $10B, with a correlation below 0.5 over the past 5 years and a positive return, are included, ranked by Sharpe ratio; funds that hold the same thing are shown once. The year columns are the years in which REGN lost money. The last two columns show a portfolio that is 80% REGN and 20% the other investment, rebalanced monthly.
ETFs
| Investment | Correlation | 5Y return | Sharpe | 2024 | 2018 | 2016 | 2008 | 2004 | 2003 | 2002 | 2001 | 1998 | 1997 | 80/20 mix volatility | 80/20 mix annual return |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| REGN Regeneron Pharmaceuticals, Inc. (this page) | 1.00 | +44.9% | 0.40 | −18.9% | −0.7% | −32.4% | −24.0% | −37.4% | −20.6% | −34.3% | −20.2% | −13.8% | −46.9% | 29.7% | +4.8% |
| LVHI InternationalFranklin International Low Volatility High Dividend Index ETF | 0.24 | +119% | 1.48 | +15.9% | −5.2% | — | — | — | — | — | — | — | — | 24.3% | +7.8% |
| DXJ InternationalWisdomTree Japan Hedged Equity Fund | 0.05 | +225% | 1.34 | +29.8% | −19.8% | +1.1% | −20.8% | — | — | — | — | — | — | 24.0% | +9.8% |
| EMLP Broad MarketFirst Trust North American Energy Infrastructure Fund | 0.10 | +101% | 1.04 | +33.4% | −8.7% | +29.8% | — | — | — | — | — | — | — | 24.2% | +7.7% |
| HDV Dividend & IncomeiShares Core High Dividend ETF | 0.26 | +83.3% | 1.00 | +14.1% | −3.0% | +15.9% | — | — | — | — | — | — | — | 24.6% | +7.0% |
| SMH TechnologyVanEck Semiconductor ETF | -0.09 | +323% | 0.97 | +39.1% | −9.1% | +35.6% | −44.7% | −19.3% | +87.3% | −47.0% | −14.6% | — | — | 24.1% | +12.6% |
| DBEF InternationalXtrackers MSCI EAFE Hedged Equity ETF | 0.13 | +85.0% | 0.96 | +13.4% | −9.5% | +6.3% | — | — | — | — | — | — | — | 24.1% | +7.3% |
| GLD CommoditiesSPDR Gold Shares | 0.02 | +126% | 0.96 | +26.7% | −1.9% | +8.0% | +4.9% | — | — | — | — | — | — | 24.1% | +8.4% |
| SPMO Broad MarketInvesco S&P 500 Momentum ETF | -0.06 | +136% | 0.93 | +45.8% | −0.9% | +7.4% | — | — | — | — | — | — | — | 23.8% | +9.1% |
Stocks
| Investment | Correlation | 5Y return | Sharpe | 2024 | 2018 | 2016 | 2008 | 2004 | 2003 | 2002 | 2001 | 1998 | 1997 | 80/20 mix volatility | 80/20 mix annual return |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| REGN Regeneron Pharmaceuticals, Inc. (this page) | 1.00 | +44.9% | 0.40 | −18.9% | −0.7% | −32.4% | −24.0% | −37.4% | −20.6% | −34.3% | −20.2% | −13.8% | −46.9% | 29.7% | +4.8% |
| CAH Medical - DistributionCardinal Health, Inc. | 0.11 | +479% | 1.55 | +19.0% | −24.5% | −17.5% | −39.6% | −4.7% | +3.5% | −8.3% | −2.5% | +51.7% | +29.1% | 24.9% | +11.9% |
| CLS Hardware, Equipment & PartsCelestica Inc. | -0.10 | +3,143% | 1.47 | +215% | −16.3% | +7.4% | −20.5% | −6.4% | +6.9% | −65.1% | −25.6% | — | — | 25.4% | +24.9% |
| FIX Engineering & ConstructionComfort Systems USA, Inc. | -0.04 | +1,636% | 1.46 | +107% | +0.8% | +18.3% | −15.2% | +40.0% | +63.6% | −9.4% | +73.7% | −9.5% | — | 25.0% | +20.7% |
| MCK Medical - DistributionMcKesson Corporation | 0.17 | +413% | 1.44 | +23.7% | −28.4% | −28.3% | −40.4% | −1.4% | +19.9% | −27.2% | +4.9% | +46.9% | +96.3% | 25.1% | +11.3% |
| MPC Oil & Gas Refining & MarketingMarathon Petroleum Corporation | 0.31 | +690% | 1.41 | −4.0% | −8.2% | +0.7% | — | — | — | — | — | — | — | 26.5% | +13.6% |
Common questions
What was REGN's worst drawdown?
REGN's deepest decline since it began trading in 1991 was 91.8%, from February 2000 to April 2005. It took about six years from the low to climb back to its old high.
What were REGN's best and worst years?
Over 29 full calendar years, REGN's best year was 2012, when it returned 209%. Its worst was 1997, with a return of -46.9%.
Is there a better investment than REGN?
Among REGN's popular alternatives, AMGN, GILD and VRTX earned more than REGN with less volatility over the past 5 years. AMGN returned 19.6% a year at 24.9% volatility, against 7.7% a year at 31.1%. Looking beyond its popular alternatives, MRK (pharmaceuticals) and TAK (pharmaceuticals) earned more than REGN with less volatility over the past 5 years. MRK returned 16.3% a year at 24.8% volatility, against 7.7% a year at 31.1%.
Is REGN more volatile than the S&P 500?
Yes. REGN's volatility over the past 5 years was 31.1%, 1.8 times the S&P 500's 17.1%. Volatility measures how widely returns swing around their average: in roughly two years out of three, REGN's return lands within 31.1% of its average, either way. The higher it is, the rougher the ride and the harder it is to hold through a slump.
What is REGN's Sharpe ratio?
REGN's Sharpe ratio over the past 5 years was 0.40, against 0.79 for the S&P 500, so REGN earned less for each unit of risk than an index fund did. The Sharpe ratio is the return earned above cash for each unit of volatility: two investments with the same return are not equal if one got there with far bigger swings.
How correlated is REGN with the S&P 500?
Over the past 5 years, REGN's monthly returns had a correlation of 0.08 with the S&P 500. Correlation runs from 1 (moving in lockstep) through 0 (unrelated) to −1 (moving in opposite directions). They are close to unrelated, or move in opposite directions, so it can steady a stock portfolio. In the table, the correlation column measures each option against REGN instead: the lower it is, the more that option would diversify a REGN holding.
What are the best alternatives to REGN?
Of the 22 popular alternatives we compared, seven outperformed REGN in at least 3 of 5 short-term and 2 of 3 long-term timeframes, with dividends reinvested: HALO, AMGN and LLY.
Did REGN outperform the S&P 500?
REGN finished ahead of the S&P 500 (SPY) in 17 of 29 full calendar years. In 2025, it returned +9.0%, against +17.7% for the index.
How did REGN do in stock market crashes?
REGN fell less than the S&P 500 (SPY) in four of the ten major crashes it has traded through, and further in six. The clearest case was the 2015 China and oil sell-off, when REGN fell 37.7% and the S&P 500 fell 12.8%.
What diversifies REGN?
These had a low correlation with REGN over the past 5 years and still earned a positive 5-year return: among large ETFs, LVHI (correlation 0.24), DXJ (correlation 0.05) and EMLP (correlation 0.10); among large stocks, CAH (correlation 0.11), CLS (correlation -0.10) and FIX (correlation -0.04). A correlation near zero means the two have moved largely independently.
How we measure
- Short-term periods are 1M, 3M, 6M, YTD, 1Y; long-term periods are 3Y, 5Y, 10Y. An investment outperformed in a period when its total return, with dividends reinvested, was higher than REGN's. Returns within 0.5 points or 3% of REGN's, whichever is larger, count as a tie.
- "Qualified" means outperforming in at least 3 of 5 short-term periods and 2 of 3 long-term periods. "All-weather" means outperforming in every long-term period and all but one short-term period.
- Popular alternatives are the funds and stocks most often compared with this one. We include only those that trade today, are not leveraged or inverse, and hold at least $200 million.
- Volatility is the annualized standard deviation of daily returns over 5 years, a measure of how much the price typically swings in a year. The Sharpe ratio is the return above cash for each unit of that volatility.
- A decline, or drawdown, runs from a peak to the lowest close before the next high. The worst decline ever uses all the price history we have; comparisons between funds use the past 10 years so that younger funds are judged on the same stretch.
- Sector overlap is the share of assets two funds hold in the same sectors. Correlation and the mixed-portfolio figures use monthly returns.
- Upside and downside capture follow Morningstar's definition: the compound monthly return in the months the S&P 500 rose (or fell), divided by the S&P 500's compound return in those months. Beta measures how strongly monthly returns have moved with the S&P 500. All three use the same window for every investment.
- Figures are computed from daily adjusted prices and update after each trading day. Past performance does not predict future results.
More research
Popular alternatives to REGN
AMGNAmgen
LLYEli Lilly and Company
GILDGilead Sciences
TMOThermo Fisher Scientific
VRTXVertex Pharmaceuticals
DHRDanaher
ARGXargenx
SNYSanofi